Viking Therapeutics (VKTX) Cash from Investing Activities (2015 - 2026)

Viking Therapeutics (VKTX) has 12 years of Cash from Investing Activities data on file, last reported at $54.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 14.32% year-over-year to $54.2 million; the trailing twelve-month figure through Mar 2026 stood at $332.3 million (up 1195.76% YoY), and the FY2025 full-year result was $341.4 million, up 161.69% from the prior year.
• Cash from Investing Activities eased to $54.2 million in Q1 2026, from $75.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $160.0 million in Q3 2025 to a low of -$459.8 million in Q1 2024.
• A 5-year average of -$16.6 million and a median of $19.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities tumbled 21018.65% in 2024 and surged 1048.42% in 2025, its largest moves.
• Tracing VKTX's Cash from Investing Activities over 5 years: stood at $7.3 million in 2022, then soared by 392.19% to $35.7 million in 2023, then sank by 81.57% to $6.6 million in 2024, then surged by 1048.42% to $75.6 million in 2025, then dropped by 28.33% to $54.2 million in 2026.
• Business Quant data shows VKTX's Cash from Investing Activities at $54.2 million in Q1 2026, $75.6 million in Q4 2025, and $160.0 million in Q3 2025.